Plain-English translation of NCT07794475 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether trimetazidine, a medication that works on how cells use energy, can help reduce the nerve pain and numbness that comes with diabetes. Researchers want to understand if this medication can ease symptoms and also affect a substance in your body called endothelin-1, which may play a role in nerve damage.
Nerve pain from diabetes is a common problem that doesn't always respond well to standard treatments. This study is exploring whether this medication could offer relief by working in a new way — through how your cells produce energy.
You likely qualify if…
You likely don't qualify if…
You would take the medication as tablets twice a day (35 mg each time) for three months while attending regular clinic visits at the diabetes center. The study will monitor your symptoms, check your blood work, and measure changes in the nerve-related substance in your blood to see if the medication is helping your pain and numbness improve.
AI-generated summary from trial data · Sep 2, 2026 · Not medical advice
Egypt